Magnetic resonance spectroscopy features of uterine leiomyomas

Basit Öğe Kaydı
dc.authoridYologlu, Saim/0000-0002-9619-3462
dc.authorwosidYologlu, Saim/ABI-8014-2020
dc.contributor.authorCelik, O
dc.contributor.authorSarac, K
dc.contributor.authorHascalik, S
dc.contributor.authorAlkan, A
dc.contributor.authorMizrak, B
dc.contributor.authorYologlu, S
dc.date.accessioned2024-08-04T20:35:41Z
dc.date.available2024-08-04T20:35:41Z
dc.date.issued2004
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: The purpose of this study is to investigate the in vivo magnetic resonance spectroscopy features of uterine leiomyomas using long echo time and to characterize the spectral patterns of these lesions. Methods: We calculated metabolites in 15 patients with uterine leiomyomas and myometrium of 20 healthy control subjects using single-voxel proton MR spectroscopy (point resolved spectroscopy technique, TE:136 ms). Voxels were placed at the center of the uterine leiomyomas. The peak areas of creatine, choline, lipid and lactate were determined. The MR spectroscopy results of uterine leiomyomas were compared with the spectroscopy results obtained from the myometrium of healthy control subjects. Results: The characteristically obtained signal was choline, which was detected not only in 14 of the 15 leiomyomas (93.3%) but also in 18 of the 20 myometrium of control subjects (90%). The lipid signals were determined in 9 of 15 patients with uterine leiomyomas (60%) and 8 of 20 control subjects (40%). The lactate signal was obtained from six of 15 patients with leiomyomas (40%) but only two of myometrium (10%). The creatine signal was obtained from 4 of 15 patients with leiomyomas (26.6%) and 5 of 20 myometrium (25%). Among the tested parameters only lactate peak was statistically significant (p < 0.05). Conclusion: Proton MR spectroscopic imaging may be helpful for the investigation of the underlying pathophysiology of uterine leiomyomas. The presence of lactate and lipid signals in the spectrum may be a useful indicator of metabolic pathway of uterine leiomyomas. Copyright (C) 2004 S. Karger AG, Basel.en_US
dc.identifier.doi10.1159/000080020
dc.identifier.endpage201en_US
dc.identifier.issn0378-7346
dc.identifier.issue4en_US
dc.identifier.pmid15286450en_US
dc.identifier.scopus2-s2.0-8344247114en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage194en_US
dc.identifier.urihttps://doi.org/10.1159/000080020
dc.identifier.urihttps://hdl.handle.net/11616/95506
dc.identifier.volume58en_US
dc.identifier.wosWOS:000225100600005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofGynecologic and Obstetric Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectproton MR spectroscopyen_US
dc.subjectuterine leiomyomaen_US
dc.subjectmyometriumen_US
dc.titleMagnetic resonance spectroscopy features of uterine leiomyomasen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu